Chardan analyst Geulah Livshits lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $20 from $22 and keeps a Buy rating on the shares. The firm is updating its model following the company’s Q1 results, reiterated guidance on its LX2006 and LX2020 programs, as well as its update on its cash position, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics reports Q1 EPS (99c), consensus (77c)
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- RBC sees Makary interview as potentially positive for biotech stocks
- Lexeo Therapeutics: Promising Cardiovascular Gene Therapy Pipeline and Strong Financial Position Justify Buy Rating
- Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc.